Replies to post #291965 on Elite Pharmaceuticals Inc (ELTP)

[mrwrn2010]

It absolutely will add revenue if the PD study is successful and docs begin prescribing this for PD patients.

[namtae]

Sure, all the other manufacturers just didnt have the foresight of Elite and discontinued manufacturing. They dont know anything about the Parkinsons study either, they've been kept in the dark and are missing out on this great opportunity

Only Elite, with their long track record of failed strategies knows this well kept secret

Of course, should everything go exactly as hoped with the Parkinsons study and the market expand exponentially for Isradipine, neither GSK nor Mylan would dare reenter manufacturing Isradipine for fear Elite could easily bully them out

Then again, maybe they know isradipine isnt the answer. If it was, why would Mikah have anything to do with it?? Their specialty is selling junk for millions to Elite

[NASDAQ2020]

The final results of the study could change Isradapine revenues exponentially.
But I don't really care because it will be a drop in thebucket compared to:

The SunGen ANDA #2 is 10-12 months from Approval

This one is Bigger than SequestOx

SunGen ANDA #2 (The Avatar) undisclosed CNS stimulant $1.6 Billion market with ONLY 3 competitors to the name brand.
Elite will split the Generic money with 3 competitors.

FDA busy reviewing submission currently.
We have 10-12 months to take advantage before Approval.

This helpful info contributed to the board by N2K shows an average amount we might receive. It could be MUCH more due to so few competitors.

For a product entering a growth market with existing product market leaders having more than a three year lead time, there has been a first year average market capture of 8.7%. If we extrapolate that to Elite and the CNS ER product for the $1.6 B market it is (that's right) $139.2 Million in the first year. And, with the Glenmark partnership as the commercialization engine, it could be better that the other two I found in my research, because Glenmark is more capable than the other two had as commercial partners.
unQuote


SunGen ANDA #3 even BIGGER than the above. approval 2019 for this one